Back to Search
Start Over
A modified human ELISPOT assay to detect specific responses to primary tumor cell targets.
- Source :
- Journal of Translational Medicine; 2004, Vol. 2, p9-11, 11p, 1 Chart, 1 Graph
- Publication Year :
- 2004
-
Abstract
- Background: The desired outcome of cancer vaccination is to induce a potent T cell response which can specifically recognize and eliminate autologous tumor cells in vivo. Accordingly, immunological assays that demonstrate recognition of native tumor cells (tumor-specific) may be more clinically relevant than assays that demonstrate recognition of tumor protein or peptide (antigen-specific). Methods: Towards this goal, we adapted the IFN-? ELISPOT assay to measure immune responses against autologous primary tumor cells in vaccinated cancer patients. As a model system to develop the assay, we utilized peripheral blood mononuclear cells (PBMC) directly isolated from follicular lymphoma patients vaccinated with tumor-derived idiotype protein. Results: After optimizing several variables, we demonstrated that the modified IFN-γ ELISPOT assay could be used to reliably and reproducibly determine the tumor-reactive T cell frequency in the PBMC of these patients. The precursor frequency of tumor-reactive T cells was significantly higher in the postvaccine PBMC, compared with prevaccine samples in all patients tested. Furthermore, the specificity of these T cells was established by the lack of reactivity against autologous normal B cells. Conclusions: These results demonstrate the feasibility of quantitating tumor-specific T cell responses when autologous, primary tumor cells are available as targets. [ABSTRACT FROM AUTHOR]
- Subjects :
- CANCER vaccines
T cells
B cells
PEPTIDES
IMMUNE response
CLINICAL trials
Subjects
Details
- Language :
- English
- ISSN :
- 14795876
- Volume :
- 2
- Database :
- Complementary Index
- Journal :
- Journal of Translational Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 28783597
- Full Text :
- https://doi.org/10.1186/1479-5876-2-9